TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00521287

Intervention type: OTHER
Group type: OTHER
Intervention: Immune profiling and DC vaccine
Description: 1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune profiling and DC vaccine
Description: 1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression.

Intervention type: OTHER
Group type: OTHER
Intervention: Immune profiling and DC vaccine
Description: 1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression.
Study: NCT03435185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injections
Description: Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injections
Description: Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
Study: NCT02271698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
Study: NCT03107260

Intervention type: OTHER
Group type: OTHER
Intervention: To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients
Description: Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
Study: NCT04247230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching placebo (PET500)
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STUD100
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Study: NCT02385851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT03790722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry H
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry L
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure.
Study: NCT00498459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical promotion according to socio-ecological model Limitation of sedentary behaviour
Study: NCT03585478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latiglutenase
Description: Latiglutenase administered orally (daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally (daily)
Study: NCT04067323

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya bean oil
Description: Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT oil
Description: Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
Study: NCT01847963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindhuvallathy mezhugu ( SVM)
Description: 500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindhuvallathy mezhugu ( SVM)
Description: 500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalladaippu Kudineer (KK) -
Description: 130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalladaippu Kudineer (KK) -
Description: 130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
Study: NCT04045327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline + Standard Treatment
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine + Standard Treatment
Description: Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Study: NCT03823183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive control
Description: Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive control
Description: Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical control
Description: Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical control
Description: Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
Study: NCT02202239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction, midazolam 0.05mg/kg will be injected intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Before induction, midazolam 0.05mg/kg will be injected intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine Hydrochloride Injection
Description: Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besilate
Description: Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besilate
Description: Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be injected continuously during maintenance of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be injected continuously during maintenance of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
Study: NCT02987725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: A 30-minute historical story read by a research clinician.
Study: NCT00409539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-986
Description: Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-986
Description: Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-986
Description: Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-986
Description: Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
Study: NCT00689312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enfalyte
Description: Each patient will receive one 250 ml dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pediatric Electrolyte
Description: Each patient will receive one 250 ml dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pedialyte
Description: Each patient will receive one 250 ml dose.
Study: NCT03830359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2769
Description: At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
Study: NCT00601497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterX 5000
Description: 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InterX 5000
Description: 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
Study: NCT01104896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
Study: NCT02609958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID
Study: NCT00662207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrator
Description: A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal dilator
Description: A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
Study: NCT03650491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR46
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR46
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
Study: NCT02172963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cell therapy
Description: Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
Study: NCT01777074

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire, Vaccination book

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire, Vaccination book
Study: NCT00957879

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50000 international units by mouth weekly for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Calcitriol 0.5 mcg by mouth daily for 12 weeks
Study: NCT03195283

Intervention type: OTHER
Intervention: Meal service
Description: The type of meal service in the hospital (usual care)

Intervention type: OTHER
Intervention: Meal service
Description: The type of meal service in the hospital (usual care)
Study: NCT02023307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc Suture
Study: NCT00374439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral
Description: Cognitive-behavioral approach

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: Interpersonal therapy approach
Study: NCT03458312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family and Network Consultations
Description: Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
Study: NCT05718466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiosurgery
Study: NCT02972203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care
Description: • MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intro. +resources +waitlist
Description: Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
Study: NCT00905515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Maintain on cyclosporine at target trough level of 50-250 ng/mL.
Study: NCT03259555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for 3 weeks.
Study: NCT00760955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 5 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 50 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 100 mg, tablets, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
Study: NCT02677168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cNEP
Description: continuous negative external pressure
Study: NCT01332994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1 g intravenously at Week 16 and 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
Study: NCT02800863

Intervention type: DEVICE
Intervention: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)
Description: Electrical stimulation of the DRG using the Axium™ Neurostimulator System

Intervention type: DEVICE
Intervention: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Description: Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
Study: NCT02584179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biparametric MRI before biopsy
Description: All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
Study: NCT03583853

Intervention type: DEVICE
Intervention: real time PCR
Description: real time PCR will be used for determination of expression of autophagy genes

Intervention type: DEVICE
Intervention: real time PCR
Description: real time PCR will be used for determination of expression of autophagy genes